Summary of Alterity Therapeutics Conference Call Company Overview - **Company**: Alterity Therapeutics (NasdaqCM:ATHE) - **Focus**: Development of therapies for neurodegenerative diseases, specifically targeting multiple system atrophy (MSA) and potentially Parkinson's disease [1][2] Industry Context - **Disease**: Multiple System Atrophy (MSA) - **Market Potential**: Estimated worldwide sales of $2.4 billion due to lack of approved treatments targeting the disease pathology [2][27] - **Patient Demographics**: Approximately 50,000 patients in the U.S. with MSA, characterized by rapid disease progression [4][6] Core Product Insights - **Lead Candidate**: ATH434 - **Phase II Results**: Demonstrated a treatment effect of up to 48% on functional endpoints in MSA patients [2][19] - **Administration**: Orally administered, preferred over intravenous or direct brain injection methods [2][11] - **Mechanism of Action**: Targets iron accumulation and alpha-synuclein aggregation in neurons, aiming to preserve neuronal function [8][10][11] Clinical Development - **Current Status**: Completed Phase II, preparing for Phase III trials [3][27] - **Key Study Design**: Randomized double-blind placebo-controlled study with 77 patients, assessing various endpoints including the modified UMSARS Part One [13][14] - **Clinical Results**: - Placebo group showed an 8-point increase in MSA rating scale, while both treatment groups showed significant reductions in decline [19] - No serious adverse events related to the drug were reported [22] Future Milestones - **Upcoming Events**: - Targeting an end-of-phase II meeting with the FDA by mid-year to discuss Phase III design [31] - Anticipated initiation of Phase III study approximately six months post-FDA meeting [31] - **Expansion Plans**: Potential to explore additional indications such as Parkinson's disease and other orphan diseases [12][35] Commercial Assessment - **Neurologist Feedback**: Over 70% of surveyed neurologists expressed strong intent to prescribe ATH434, highlighting the unmet need in treating MSA [26] - **Sales Projections**: Peak sales estimated at $2.4 billion, reinforcing the commercial viability of ATH434 [27][39] Additional Considerations - **Research Collaborations**: Ongoing collaboration with the Michael J. Fox Foundation for research in Parkinson's disease [4] - **Regulatory Designations**: ATH434 has orphan drug designation in the U.S. and EU, along with fast track designation from the FDA [12] Conclusion - **Strategic Positioning**: Alterity Therapeutics is well-positioned to advance ATH434 through clinical trials, with significant market potential and a strong focus on addressing critical unmet needs in neurodegenerative diseases [27][39]

Core Insights - The publication in JAMA Neurology presents significant findings from the PARADIGM Phase 2b trial of PrimeC in ALS, indicating meaningful clinical outcomes and biological activity [1][5][6] Study Overview - PARADIGM was a randomized, double-blind, placebo-controlled trial assessing PrimeC's safety and efficacy over a 6-month treatment period followed by a 12-month open-label extension [3][8] - The trial enrolled 68 participants with definite or probable ALS, randomized in a 2:1 ratio to receive PrimeC or placebo [8] Clinical Outcomes - PrimeC treatment resulted in a 64% relative reduction in the risk of ALS-related complications, including respiratory failure and hospitalization (p=0.02) [6][10] - Continuous treatment with PrimeC showed a 7.92-point advantage in ALSFRS-R at 18 months, representing over a 36% benefit in slowing disease progression (p=0.007) [6][9] - Significant improvement in bulbar function was observed (p=0.001) [6][9] Safety Profile - PrimeC demonstrated a safety profile comparable to placebo over 18 months, with most treatment-related adverse events being mild to moderate and transient [6][7] Biomarker Findings - The trial showed significant modulation of ALS-related microRNAs and iron-regulatory biomarkers, supporting PrimeC's biological activity [6][12] - Favorable changes in markers of iron metabolism were observed, including preservation of transferrin levels and stabilization of ferritin [11][12] Future Development - The findings support the advancement of PrimeC to a Phase 3 clinical trial, which has received FDA clearance [6][7][8] - The consistent results across clinical outcomes and biomarkers provide a strong scientific foundation for further evaluation of PrimeC as a potential disease-modifying therapy [6][7][12]

Core Viewpoint - Alterity Therapeutics is advancing its ATH434 program for Multiple System Atrophy (MSA), with strengthened Phase 2 data and a solid cash position, while preparing for a pivotal Phase 3 clinical trial and engaging with the FDA [2][3][7]. Phase 2 Clinical Program & Regulatory Progress - The company has made significant progress in its Phase 2 trial for ATH434, with new analyses enhancing confidence in its potential as a disease-modifying therapy for MSA, projecting a commercial opportunity of US$2.4 billion [3][4]. - Preparations for an End-of-Phase 2 meeting with the FDA are underway, aimed at aligning on the design and requirements for a pivotal Phase 3 trial [5][9]. - A new analysis from the Phase 2 trial showed an improved efficacy signal in the 75 mg dose group, with a relative treatment effect increase from 30% to 35% compared to placebo [6]. Cash Position - As of December 31, 2025, the company reported a cash balance of A$49.2 million, with operating cash outflows of A$5.28 million for the quarter, providing a solid runway for regulatory and clinical objectives [21]. Corporate and Financial Update - The governance and leadership structure has been strengthened to support the transition into late-stage development, with key appointments made to enhance strategic execution [15][20]. - The company is exploring non-dilutive funding pathways for Phase 3 development through ongoing discussions with pharmaceutical partners [7][14]. Scientific and Clinical Engagement - Alterity has actively engaged with the global neurology community through scientific presentations, which are crucial for disseminating clinical data and refining interpretations of Phase 2 results [11][12]. - A Clinical Advisory Board meeting was held to review Phase 2 data and provide expert input for the Phase 3 trial design [12]. Outlook - The company is focused on advancing ATH434 toward a pivotal Phase 3 program, ensuring regulatory alignment with the FDA, and pursuing strategic partnerships to maximize long-term shareholder value [23].

Core Insights - Idorsia Ltd has published results from the pivotal Phase 3 MODIFY study and its open-label extension, highlighting the potential of lucerastat as an oral substrate reduction therapy for Fabry disease, particularly in patients with renal impairment [1][3]. Study Overview - The MODIFY study was a multicenter, double-blind, randomized, placebo-controlled trial involving 118 patients, aimed at assessing the efficacy and safety of lucerastat as an oral monotherapy for adult patients with Fabry disease [2]. - The study's primary endpoint of reducing neuropathic pain over six months was not met; however, lucerastat showed significant reductions in plasma and urinary Gb3 levels compared to placebo, with sustained effects observed in the open-label extension [3][17]. Renal Function Insights - An interim analysis of the open-label extension indicated a notable improvement in renal function trajectory, with a reduced rate of eGFR decline in patients treated with lucerastat compared to their eGFR slope prior to enrollment [4][9]. - In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a significant reduction in kidney function loss, suggesting a potential disease-modifying effect [4][17]. Long-term Treatment and Tolerability - The open-label extension has collected data from patients treated with lucerastat for over 42 months, with some receiving treatment for more than 6 years, demonstrating good tolerability and no serious treatment-related adverse events [5][8]. - A kidney biopsy sub-study was conducted to evaluate Gb3 inclusions in kidney cells of male participants with classic Fabry disease treated for over 3 years with lucerastat [5]. Future Directions - The company is collaborating with the US FDA to design a new Phase 3 program to ensure a regulatory pathway for lucerastat's approval [6][10]. - A post-trial access program is being established to ensure continuity of care for participants still receiving lucerastat at the study's closure [7].

Core Insights - Zorevunersen shows potential as a disease-modifying therapy for Dravet syndrome, supported by four years of clinical data and EEG assessments [1][2][3] Company Overview - Biogen Inc. is a leading biotechnology company focused on innovative science to develop new medicines [7] - Stoke Therapeutics specializes in RNA medicine aimed at restoring protein expression, with zorevunersen as its first investigational product [9] Product Information - Zorevunersen is an investigational antisense oligonucleotide targeting the underlying cause of Dravet syndrome by increasing NaV1.1 protein production [5] - The drug has received orphan drug designation and Breakthrough Therapy Designation from the FDA for Dravet syndrome [5] Clinical Studies - The ongoing EMPEROR Phase 3 study evaluates zorevunersen's efficacy in children with Dravet syndrome, focusing on seizure frequency and cognitive improvements [6] - Data from the Phase 1/2a and ongoing open-label extension studies will be presented at the 2025 American Epilepsy Society Annual Meeting [2][3] Disease Context - Dravet syndrome is characterized by severe seizures and cognitive impairments, with a significant portion of patients not achieving adequate seizure control with existing treatments [4] - Approximately 38,000 individuals are estimated to be living with Dravet syndrome in the U.S., UK, EU-4, and Japan [4]

Core Insights - Galectin Therapeutics Inc. presented findings from the NAVIGATE study, focusing on the efficacy of belapectin, a galectin-3 inhibitor, in treating patients with compensated MASH cirrhosis and portal hypertension [1][2] Study Overview - The NAVIGATE trial was a Phase 2b randomized, double-blind, placebo-controlled study involving 355 patients, assessing the effects of belapectin administered at doses of 2 mg/kg and 4 mg/kg every other week for 18 months [2] - The study aimed to evaluate the impact of belapectin on the incidence of new esophageal varices and liver fibrosis progression [2][4] Efficacy Results - Belapectin 2 mg/kg showed a significantly lower incidence of new varices compared to placebo, particularly in patients with an ELF score >11.3 (22.7% vs 42.9%) [3][4] - At 18 months, patients receiving 2 mg/kg belapectin achieved a mean reduction of 6.4 ng/mL in Pro-C3 levels, indicating over 50% improvement from baseline [3][5] - The treatment also demonstrated a lower incidence of clinically meaningful worsening in liver stiffness compared to placebo, suggesting a slowing of fibrosis progression [4] Biomarker Analysis - Analysis of YKL-40 showed a ≥20% reduction in a higher proportion of patients treated with belapectin 2 mg/kg compared to placebo (33.8% vs 23.1%), supporting its antifibrotic activity [6][7] - PRO-C4 analysis indicated a ≥20% increase from baseline occurred more frequently in placebo-treated patients (13% vs 3%), reinforcing belapectin's potential to modify disease progression [7] Long-term Outcomes - The reduction in new varices observed at 18 months was sustained through 36 months, with cumulative incidences of new varices at 36 months being 23.4% for placebo, 12.4% for 2 mg/kg, and 16.7% for 4 mg/kg cohorts [8] - The safety profile of belapectin remained favorable, with adverse events comparable across treatment groups and no drug-related serious adverse events reported [9] Expert Commentary - Experts highlighted the long-term NAVIGATE data as significant, noting the sustained improvements in liver stiffness and biomarkers, which suggest a consistent antifibrotic effect [10] - The company expressed optimism about advancing regulatory discussions and exploring partnerships to further develop belapectin, emphasizing its potential to address a significant unmet medical need in MASH cirrhosis [10][11]

Core Insights - Alterity Therapeutics is focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Multiple System Atrophy (MSA) [2][16] - The company reported positive clinical results for its lead asset, ATH434, and highlighted a potential market opportunity of approximately USD 2.4 billion for MSA treatments [4][13] Financial Overview - As of September 30, 2025, Alterity's cash position was A$54.56 million, with operating cash outflows of A$5.34 million for the quarter [5][9] - The company raised A$20 million in gross proceeds from a strategic placement to advance its programs [14] Clinical Development - Positive results from the ATH434-201 Phase 2 clinical trial showed a relative treatment effect of 35% in the 75 mg dose group at 52 weeks [8][10] - The ATH434-202 open-label trial demonstrated comparable efficacy to earlier-stage patients, confirming ATH434's favorable profile [10][16] - The company is engaging with the U.S. FDA to discuss data required for Phase 3 trials, with an End-of-Phase 2 meeting expected in mid-2026 [7][4] Regulatory and Market Engagement - ATH434 has received Fast Track Designation from the FDA, allowing for a series of Type C meetings to discuss necessary data for Phase 3 [6][7] - An independent commercial assessment indicated strong physician interest in ATH434, with over 70% of surveyed neurologists likely to prescribe it based on Phase 2 data [13] Research and Innovation - The company published findings from the bioMUSE Natural History Study, introducing the MSA Atrophy Index as a potential diagnostic tool for MSA [11] - Ongoing presentations at major conferences highlight the clinical progress and potential of ATH434 in treating MSA [12][16]

Core Insights - Annovis Bio, Inc. announced new results indicating that its drug candidate, buntanetap, can reduce inflammation and improve cellular health in Alzheimer's patients, suggesting potential disease-modifying effects beyond just symptomatic relief [1][2]. Group 1: Clinical Study Results - The Phase 2/3 study analysis showed that buntanetap effectively targets key biomarkers of neuroinflammation and neurodegeneration, leading to reductions in inflammatory markers such as IL-5, IL-6, S100A12, IFN-γ, and IGF1R compared to placebo [2]. - Buntanetap also decreased levels of neurofilament light chain (NFL), a marker of neuronal damage, indicating improved cellular integrity and neuronal health, particularly in patients with positive pTau217 plasma levels [2][3]. Group 2: Mechanism and Therapeutic Potential - The drug's ability to target multiple neurotoxic proteins simultaneously is highlighted as a significant advantage, potentially interrupting the toxic cascade associated with Alzheimer's disease [3]. - Previous clinical benefits were noted in mild Alzheimer's patients, who experienced significant cognitive improvements, reinforcing the potential of buntanetap as a disease-modifying therapy [3]. Group 3: Ongoing Research and Future Outlook - Buntanetap is currently undergoing a pivotal Phase 3 trial in early Alzheimer's disease, with a 6-month readout focused on symptomatic improvement and an 18-month readout aimed at assessing disease modification [3][4]. - The full biomarker data will be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in December 2025, which is expected to provide further insights into the drug's efficacy [4].

Zorevunersen for Dravet Syndrome - Stoke Therapeutics is developing zorevunersen as a potential disease-modifying medicine for Dravet syndrome [16] - Initial 70mg doses of zorevunersen demonstrated substantial and sustained reductions in convulsive seizure frequency [18] - Ongoing zorevunersen treatment showed substantial and durable reductions in major motor seizure frequency in OLE studies [21] - 36-month OLE data shows continuing improvements in cognition and behavior with zorevunersen treatment [56] - The EMPEROR Phase 3 study is designed to assess disease modification in Dravet syndrome with a dosing regimen of 2x70mg followed by 2x45mg over a 52-week treatment period [31, 32] - The EMPEROR Phase 3 study has dosed its first patient in August 2025 and anticipates data in 2H 2027, randomizing approximately 170 patients across ~70 global sites [35] STK-002 for Autosomal Dominant Optic Atrophy (ADOA) - Approximately 65-90% of ADOA cases are caused by mutations in one allele of the OPA1 gene, leading to haploinsufficiency [64] - Up to 46% of ADOA patients are registered as legally blind [65] - Preclinical findings support further development of STK-002, showing increased OPA1 protein and ATP-linked respiration [70] - A Phase 1 study of STK-002 in ADOA patients is underway in the UK, involving 21 patients aged ≥18 to <55 years receiving single ascending doses (0.1, 0.3, 0.5, & 0.7 mg/eye) [76]

Core Insights - Scinai Immunotherapeutics Ltd. has published new peer-reviewed research confirming the efficacy and safety of PC111, a human anti-Fas Ligand monoclonal antibody, in treating pemphigus and other skin conditions [1][2][3] Scientific and Clinical Findings - The new study validates PC111's ability to prevent blister formation in humanized models of pemphigus by targeting soluble Fas Ligand, which is crucial for keratinocyte apoptosis [2][3] - PC111 has shown significant reduction in disease activity in a proprietary humanized FasL mouse model, confirming its non-immunosuppressive action at the keratinocyte level [3] - The research also indicates PC111's potential in treating Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), a severe dermatological condition [4] Market Opportunity - Current treatments for pemphigus and SJS/TEN involve chronic immunosuppression, which can have serious side effects; PC111 offers a differentiated, fast-acting, and safer therapeutic profile [5][6] - The combined market opportunity for pemphigus and SJS/TEN is estimated to exceed one billion dollars annually [6] Development Strategy - Scinai plans to advance PC111 through IND-enabling studies and clinical development, with orphan drug designation already granted in the EU and similar status sought in the U.S. [7] - The companies are exploring accelerated approval pathways that could facilitate market entry within three to four years [7] Program Structure and Leadership - The PC111 program is led by a team of experts including Prof. Carlo Pincelli and Dr. Antonino Amato, supported by Scinai's Scientific Advisory Board [8] - The efficacy of PC111 is backed by multiple peer-reviewed publications, enhancing its credibility [8] - Scinai may receive up to 80% cost coverage through a €15 million FENG grant to support development [8] Regulatory and Strategic Outlook - The combination of orphan designation, high unmet medical need, and a well-defined mechanism of action supports a realistic path toward Breakthrough Therapy designation and/or Accelerated Approval [9]